Short androgen suppression and radiation dose escalation for intermediate-and high-risk localized prostate cancer: Results of EORTC trial 22991

Journal of Clinical Oncology

Volumn 34, Issue 15, 2016, Pages 1748-1756

  Bolla, Michel ^f   Maingon, Philippe ^j   Carrie, Christian ^b   Villa, Salvador ^c   Kitsios, Petros ^d   Poortmans, Philip M P ^e   Sundar, Santhanam ^g   Van Der Steen Banasik, Elzbieta M ^h   Armstrong, John ⁱ   Bosset, Jean François ^k   Herrera, Fernanda G ^l   Pieters, Bradley ^m   Slot, Annerie ⁿ   Bahl, Amit ⁱ   Ben Yosef, Rahamim ^o   Boehmer, Dirk ^p   Scrase, Christopher ^q   Renard, Laurette ^r   Shash, Emad ^s   Coens, Corneel ^s   Van Den Bergh, Alphonsus C M ^a   Collette, Laurence ^s   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CENTRE LÉON BÉRARD   (France)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Bank of Cyprus Group Oncology Centre   (Cyprus)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h Arnhems Radiotherapeutisch Instituut   (Netherlands)

ⁱ ST LUKE S HOSPITAL   (Ireland)

^j CENTRE GEORGES FRANÇOIS LECLERC   (France)

^k UNIVERSITY HOSPITAL OF BESANÇON   (France)

^l LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ Radiotherapeutisch Instituut Friesland   (Netherlands)

^o Oncology Institute   (Israel)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q IPSWICH HOSPITAL   (United Kingdom)

^r CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^s EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; GONADORELIN AGONIST; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

AGED; ANALYSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; DEATH; DIARRHEA; FOLLOW UP; GLEASON SCORE; GYNECOMASTIA; HAZARD RATIO; HIGH RISK POPULATION; HOT FLUSH; HUMAN; IMAGING; INTENTION TO TREAT ANALYSIS; INTERMEDIATE RISK PATIENT; INTESTINE OBSTRUCTION; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE ESCALATION; SEXUAL DYSFUNCTION; TREATMENT DURATION; ANTIANDROGEN THERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HIGH RISK PATIENT; INTENSITY MODULATED RADIATION THERAPY; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; ADULT; BLOOD; CONTROLLED STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 84969548933     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.8055     Document Type: Article

References (35)

1. Schrö der FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328, 2009
2. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974, 1998
3. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295-300, 1997
4. BollaM, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360: 103-106, 2002
5. Bolla M, de Reijke TM, Van Tienhoven G, et al; EORTC Radiation Oncology Group and Genito- Urinary Tract Cancer Group: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360: 2516-2527, 2009
6. Horwitz EM, Bae K, Hanks GE, et al: Tenyear follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26: 2497-2504, 2008
7. Pilepich MV, Winter K, Lawton CA, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285-1290, 2005
8. Heidenreich A, Bastian PJ, Bellmunt J, et al; European Association of Urology: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65: 467-479, 2014
9. D'Amico AV, Chen MH, Renshaw AA, et al: Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299: 289-295, 2008
10. Jones CU, Hunt D, McGowan DG, et al: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365: 107-118, 2011
11. Valicenti RK, Bae K, Michalski J, et al: Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys 79: 1323-1329, 2011
12. DenhamJW, Steigler A, Lamb DS, et al: Shortterm neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12: 451-459, 2011
13. Sobin LH, Fleming ID: TNM classification of malignant tumors (ed 5). Cancer. 80: 1803-1804, 1997
14. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103-115, 1975
15. International Commission on Radiation Units andMeasurements. Prescribing, recording and reporting photon beam therapy. Report 50. Bethesda,MD, ICRU, 1993
16. Matzinger O, Duclos F, van den Bergh A, et al; EORTC Radiation Oncology Group: Acute toxicity of curative radiotherapy for intermediate- And high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 45: 2825-2834, 2009
17. Matzinger O, Poortmans P, Giraud JY, et al; EORTC Radiation Oncology Group: Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: Dummy run and individual case review. Radiother Oncol 90: 285-290, 2009
18. Cancer Therapy Evaluation Program Common Toxicity Criteria: Version 2.0 DCTD, NCI, NIH, DHHS March 1998 National Cancer Institute of Canada Clinical Trials Group. Expanded common toxicity criteria. Kingston, ON, National Cancer Institute of Canada Clinical Trials Group, 1994, pp 1-35
19. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341-1346, 1995
20. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376, 1993
21. van Andel G, Bottomley A, Foss°a SD, et al: An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 44: 2418-2424, 2008
22. Roach M III, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65: 965-974, 2006
23. Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41: 491-500, 1998
24. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1: 121-129, 1982
25. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data, 2nd ed. New York, NY, John Wiley, 2002
26. Cox DR: Regression models and life-tables. J R Stat Soc Series B Stat Methodol 34: 187-220, 1972
27. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16: 1141-1154, 1988
28. Fayers P, Aaronson NK, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual, 3rd ed. Brussels, Belgium, EORTC Publications, 2001
29. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16: 139-144, 1998
30. Dearnaley DP, Jovic G, Syndikus I, et al: Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15: 464-473, 2014
31. Kuban DA, Tucker SL, Dong L, et al: Long-term results of the M. D. Anderson randomized doseescalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70: 67-74, 2008
32. Zietman AL, DeSilvio ML, Slater JD, et al: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294: 1233-1239, 2005
33. Peeters STH, Heemsbergen WD, Koper PCM, et al: Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24: 1990-1996, 2006
34. Zelefski MJ, Yamada Y, Pei X, et al: Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 77: 986-990, 2011
35. Nabid A, Carrier N, Martin AG, et al: High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study. J Clin Oncol 31, 2013 (suppl 6; abstr 3)